RAD1901: Clinical Trials

7 trials of RAD1901, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 recruiting, 1 terminated, 1 withdrawn. 7 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 3, Recruiting 2, Terminated 1, Withdrawn 1
Phase 25Recruiting 2, Completed 1, Terminated 1, Withdrawn 1

Follow RAD1901: new trials by email Literature Review of RAD1901 trials Research Report on RAD1901

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Elacestrant, Trastuzumab Deruxtecan - Metastatic Breast Cancer, HER2 Low Breast Carcinoma
Phase 1 / Phase 2RecruitingKristina A. Fanucci652025-11-172026-06-10
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
Samuraciclib, Elacestrant Dihydrochloride - Metastatic Breast Cancer, Locally Advanced Breast Cancer
Phase 1 / Phase 2CompletedCarrick Therapeutics Limited492023-10-092026-03-23
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Elacestrant, Onapristone - Breast Cancer
Phase 1 / Phase 2WithdrawnContext Therapeutics Inc.2023-06-012025-04-22
A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
Elacestrant dihydrochloride - Hepatic Impairment
Phase 1CompletedStemline Therapeutics, Inc.162023-03-132024-11-19
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
Elacestrant, Onapristone - Breast Cancer
Phase 1 / Phase 2TerminatedContext Therapeutics Inc.42022-12-022026-07-21
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Elacestrant, Abemaciclib - Breast Neoplasms, Brain Neoplasms
Phase 1 / Phase 2RecruitingStemline Therapeutics, Inc.732022-08-312026-10-09
Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer
RAD1901 - Metastatic Breast Cancer
Phase 1CompletedStemline Therapeutics, Inc.162016-04-012022-08-18

Conditions studied

Breast Neoplasms (7)  ·  Brain Diseases (1)  ·  Brain Neoplasms (1)  ·  Breast Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Central Nervous System Neoplasms (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)

Sponsors

Stemline Therapeutics, Inc. (3)  ·  Context Therapeutics Inc. (2)  ·  Carrick Therapeutics Limited (1)  ·  Kristina A. Fanucci (1)

Countries

United States (6)  ·  Belgium (2)  ·  France (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Germany (1)  ·  Greece (1)  ·  Italy (1)  ·  Netherlands (1)  ·  South Korea (1)  ·  Turkey (Türkiye) (1)

Top investigators

Elisabeth GE de Vries, MD (1)  ·  Kristina Fanucci, MD (1)

Results publications

PMID 32912274

NIH funding

2015 (1), 2023 (1)